The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
24 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,763,435 in first-year total cost, median $272,492.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-F (56)]23
- Special Emphasis Panel[ZRG1 SBIB-H (56)]1
Most frequent institutions
- DUKE UNIVERSITY2
- MAYO CLINIC ROCHESTER2
- SLOAN-KETTERING INST CAN RESEARCH2
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE1
- CHILDREN'S RESEARCH INSTITUTE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Multi-site Validation and Application of a Consensus DSC MRI Protocol1R01CA221938-01 | BOXERMAN, JERROLD LHU, LELANDQUARLES, CHRISTOPHER CHADSCHMAINDA, KATHLEEN MARIE | ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER, AZ | $295,825 | ZRG1 |
| 2017 | A First-in-Human Pilot Study of 18F-MFBG Imaging for Evaluation of Neuroblastoma1R01CA204093-01A1 | PANDIT TASKAR, NEETA | SLOAN-KETTERING INST CAN RESEARCH, NY | $392,078 | ZRG1 |
| 2017 | Quantitative Staging and Therapeutic Response in IDH-1 Mutated Glioblastomas1R01CA200808-01A1 | SOHER, BRIAN J | DUKE UNIVERSITY, NC | $359,205 | ZRG1 |
| 2017 | First in human study with 18F-avb6-targeting peptide1R01CA211554-01A1 | SUTCLIFFE, JULIE L | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $354,083 | ZRG1 |
| 2017 | Spectroscopic MRI to guide radiation dose escalation for glioblastoma patients1R01CA214557-01 | SHIM, HYUNSUKSHU, HUI-KUO | EMORY UNIVERSITY, GA | $312,894 | ZRG1 |
| 2017 | imaging Radiation-Associated Dysphagia (iRAD)1R01CA218148-01 | FULLER, CLIFTON DAVIDHUTCHESON, KATHERINE ARNOLD | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $261,800 | ZRG1 |
| 2017 | Evaluation of metastatic brain tumor heterogeneity and physiological response to immunotherapy using advanced MRI1R01CA211238-01 | GERSTNER, ELIZABETH | MASSACHUSETTS GENERAL HOSPITAL, MA | $108,103 | ZRG1 |
| 2016 | Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia1R01CA195519-01A1 | FORMAN, STEPHEN JSTEIN, ANTHONYWONG, JEFFREY Y | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $272,213 | ZRG1 |
| 2016 | 3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis1R01CA195443-01A1 | HRISTOV, DIMITRE HRISTOVWILLMANN, JUERGEN KARL | STANFORD UNIVERSITY, CA | $255,216 | ZRG1 |
| 2016 | Quantitative multiphoton microscopy for non-invasive diagnosis of melanoma1R01CA195466-01A1 | KELLY, KRISTEN MTROMBERG, BRUCE J. | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $252,801 | ZRG1 |
| 2016 | A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR1R01CA200551-01 | DONG, HAIDONGPARK, SEAN S | MAYO CLINIC ROCHESTER, MN | $247,249 | ZRG1 |
| 2016 | Reproducibility of Hyperpolarized Pyruvate Metabolic Imaging in Prostate Cancer1R01CA195476-01A1 | HRICAK, HEDVIGKESHARI, KAYVAN R | SLOAN-KETTERING INST CAN RESEARCH, NY | $246,700 | ZRG1 |
| 2016 | Clinical trial personalizing radiation therapy through a novel lung function imaging modality1R01CA200817-01 | VINOGRADSKIY, YEVGENIY | UNIVERSITY OF COLORADO DENVER, CO | $218,591 | ZRG1 |
| 2016 | First in-human PET imaging studies of NIS reporter [18F]BF41R01CA196975-01A1 | DEGRADO, TIMOTHY R. | MAYO CLINIC ROCHESTER, MN | $156,394 | ZRG1 |
| 2015 | Assessing the Role of [11C]Vorozole in the Detection of Aromatase in Breast Cancer1R01CA195506-01 | BIEGON, ANATCOHEN, JULES A | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $390,089 | ZRG1 |
| 2015 | Validating Low FDG Dose PET/CT compared to current Standard of Care Dose PET/CT1R01CA195513-01 | KNOPP, MICHAEL VZHANG, JUN | OHIO STATE UNIVERSITY, OH | $352,275 | ZRG1 |
| 2015 | Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer1R01CA195505-01 | MARKS, LEONARD STEPHEN | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $352,275 | ZRG1 |
| 2015 | Early phase clinical trial for imaging tumor acidosis in breast cancer patients using acidoCEST MRI1R01CA197029-01 | PAGEL, MARK DAVID | UNIVERSITY OF ARIZONA, AZ | $349,892 | ZRG1 |
| 2015 | Reducing mastectomy rates in invasive lobular carcinoma by high-resolution 3D breast CT1R01CA195512-01 | VEDANTHAM, SRINIVASAN | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $306,525 | ZRG1 |
| 2015 | ASSESSMENT OF FUNCTIONAL STATUS OF ESTROGEN RECEPTORS IN BREAST CANCER BY PET1R01CA195450-01 | DEHDASHTI, FARROKH | WASHINGTON UNIVERSITY, MO | $279,075 | ZRG1 |
| 2015 | Early Phase Clinical Trials in Imaging and Image-Guided Interventions1R01CA197137-01 | KIM, AERANG | CHILDREN'S RESEARCH INSTITUTE, DC | $272,770 | ZRG1 |
| 2015 | Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer1R01CA195493-01 | CONTESSA, JOSEPH NMORRIS, EVAN D | YALE UNIVERSITY, CT | $254,873 | ZRG1 |
| 2015 | Effectiveness of IG-IMRT for Locally Advanced Cervix Cancer on NRG Trial CVM-14211R01CA197059-01 | MELL, LOREN K. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $253,619 | ZRG1 |
| 2015 | A Viable Solution for a See and Treat Paradigm for Cervical Pre-cancer in Africa1R01CA195500-01 | RAMANUJAM, NIRMALA | DUKE UNIVERSITY, NC | $218,890 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.